Bonesupport
The market submission for CERAMENT® V in the US will be a 510(k)
BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces that the company’s submission for marketing authorization for its antibiotic eluting bone graft substitute, CERAMENT V (vancomycin), following discussions with the U.S. Food and Drug Administration (FDA), will proceed through a 510(k) pathway, instead of a De Novo application.
The marketing approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. Since CERAMENT V shares the same mechanism of action as CERAMENT G, despite containing a different antibiotic, CERAMENT G can serve as a predicate device for CERAMENT V. The submission is still scheduled for the first quarter of 2025.
CERAMENT V has previously received “breakthrough device” designation from the FDA for the indication bone infection.
| Datum | 2024-07-01, kl 14:30 |
| Källa | MFN |
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID